Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
NCT03896945Phase 3Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Feb 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of deudextromethorphan in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Feb 2019; status: terminated.
02
Drugs
deudextromethorphan
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03896945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896945.